Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide effects on neuroplasticity in Parkinson's disease
2017-002239-41Phase 4Terminated
- Sponsor
- Fondazione Santa Lucia IRCCS
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of safinamide in Parkinson's disease (PD), sponsored by Fondazione Santa Lucia IRCCS. Primary endpoint: Change in LTP-like cortical plasticity. Started Jun 2021; status: terminated.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2017-002239-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002239-41.